Recent additions to the NLM Drug Information Portal include clinical experience with drugs and dietary supplements
From the NLM-TOX-ENVIRO-HEALTH-L Digest – 2 Oct 2014 to 7 Oct 2014 (#2014-19)
The National Library of Medicine (NLM) Drug Information Portal (http://druginfo.nlm.nih.gov) is a free web resource that provides an informative, user–friendly gateway to current drug information for over 53,000 substances. The Portal links to sources from the NLM, the National Institutes of Health (NIH), and other government agencies such as the U.S. FDA.
Current information regarding consumer health, clinical trials, AIDS–related drug information, MeSH® pharmacological actions, PubMed® biomedical literature, and physical properties and structure is easily retrieved by searching a drug name. A varied selection of focused topics in medicine and drug–related information is also available from displayed subject headings.
The Drug Portal retrieves by the generic or trade name of a drug or its category of usage. Records provide a description of how the drug is used, its chemical structure and nomenclature, and include up to 20 Resource Locators which link to more information in other selected resources. Recent additions to these Locators include clinical experience with drugs in PubMed Health (http://www.ncbi.nlm.nih.gov/pubmedhealth), substances reviewed in NLM LiverTox (http://livertox.nih.gov/), information from the Dietary Supplement Label Database (http://dsld.nlm.nih.gov/dsld/), and drug images in the Pillbox beta (http://pillbox.nlm.nih.gov/) database.
Data in the Drug Information Portal is updated daily, and is also available on mobile devices.
More information can be found at http://www.nlm.nih.gov/pubs/factsheets/druginfoportalfs.html
11/30/12 | 9:00:00 AM
Labels: knowledge graph
We get a lot of queries for medicine on Google. So to make it quick and easy for you to learn about medications, we’ll start showing key facts — side effects, related medications, links to in-depth resources, and more — right on the search results page.
This data comes from the U.S. FDA, the National Library of Medicine, and the Department of Veterans Affairs, among others. It’s part of the Knowledge Graph — our project to map out billions of real-world things, from famous artists to roller coasters to planets (and now medications). We hope you find this useful, but remember that these results do not act as medical advice.
Posted by Aaron Brown, Senior Product Manager, Search
Related Resources (because there are other reputable resources besides the one’s Google mines! with additional drug info)
Once a medication is identified, Pillbox provides links to drug information and drug labels.
- CenterWatch/Clinical Trials Listing Service
This useful resource lists newly approved drugs, drugs in current clinical research, weekly trial results, as well as a link to the PDR Family Medical Guide for Prescription Drugs.
- Longwood Herbal Task Force
This site has in-depth monographs about herbal products and supplements written by health professionals and students. It provides clinical information summaries, patient fact sheets, and information about toxicity and interactions as well as relevant links. The task force is a cooperative effort of the staff and students from Children’s Hospital, the Massachusetts College of Pharmacy and Health Sciences, and the Dana Farber Cancer Institute.
- FDA Recalls provides information gathered from press releases and other public notices about certain recalls of FDA-regulated products
- Herbal and Dietary Supplements Can Adversely Affect Prescribed Drugs, Says Extensive Review (jflahiff.wordpress.com)
- Natural Does Not Mean Safe (slate.com)
- Warning out on supplements (newsinfo.inquirer.net)
- Drug industry’s free speech helps doctors (cnn.com)
- Supplements not on an FDA approved list could disappear (prn.fm)
- Look up medications more quickly and easily on Google (insidesearch.blogspot.com)
- Google Adds Key Facts About Medicines To Its Knowledge Graph Results (techcrunch.com)
- Google: This is your Knowledge Graph on drugs (news.cnet.com)
A free source of evidence-based information for health care professionals and for researchers studying liver injury associated with prescription and over-the-counter drugs, herbals, and dietary supplements is now available from the National Institutes of Health. Researchers and health care professionals can use the LiverTox database to identify basic and clinical research questions to be answered and to chart optimal ways to diagnose and control drug-induced liver injury.
Drug-induced liver injury is the leading cause of acute liver failure in the United States, accounting for at least half of cases. It occurs at all ages, in men and women, and in all races and ethnic groups. Drug-induced liver disease is more likely to occur among older adults because they tend to take more medications than younger people. Some drugs directly damage the liver, while others cause damage indirectly or by an allergic reaction. The most important element to managing drug-induced liver injury is to identify the drug that’s causing the problem and appropriate steps to eliminate or reduce damage to the liver.
“Because drug-induced liver disease is not a single, common disease, it is very difficult to diagnose, with each drug causing a somewhat different pattern of liver damage,” said Jay H. Hoofnagle, M.D., the major creator of LiverTox and director of the Liver Disease Research Branch at NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Doctors have to rule out all other causes of liver disease before saying that a patient has drug-induced injury liver.”
LiverTox has a searchable database of about 700 medications available in the United States by prescription or over the counter. Over the next few years, another 300 drugs will be added. The database offers these features:
- An overview of drug-induced liver injury, including diagnostic criteria, the role of liver biopsy, descriptions of different clinical patterns and standard definitions.
- A detailed report of each drug, including background, case study, product package insert, chemical makeup and structure, dose recommendations and references with links.
- An interactive section, allowing users to report cases of drug-induced liver injury to the LiverTox website. Reports will be automatically forwarded to the Food and Drug Administration’s (FDA) MedWatch program. MedWatch allows the public and health care professionals to report adverse events, product defects, or product use errors. The FDA uses the information to monitor product safety.
“LiverTox is the result of a significant scientific collaboration between the national and international clinical and research communities, the NIDDK and the National Library of Medicine (NLM),” said Steven Phillips, M.D., co-sponsor of LiverTox and director of NLM’s Division of Specialized Information Services. “LiverTox demonstrates the importance of using informatics to provide easy access to evidenced-based information to clinicians and researchers that will improve the health and well-being of all and help prevent unnecessary morbidity and mortality, worldwide. I hope the dynamic LiverTox model can be used to create a new suite of databases that can identify drug-induced injury to other organs such as the heart, kidney, and lung. The National Library of Medicine is honored to be part of this significant scientific endeavor.”
- NIH launches LiverTox a free database of drugs linked to liver injury (hslnews.wordpress.com)
- NIH launches free database of drugs associated with liver injury (medicalxpress.com)
- Drug Induced Liver Dysfunction Lab Values (jessicamhpower.wordpress.com)
Now one can get summary and detailed drug information on the go from reputable resources
From a recent email rec’d from the US National Library of Medicine
The National Library of Medicine (NLM) Drug Information Portal is now available for mobile devices.http://druginfo.nlm.nih.gov/m.drugportal
This mobile optimized web site covers over 32,000 drugs and provides descriptions, drug names, pharmaceutical categories, and structural diagrams. Each record also features information links to 19 other resources including NLM PubMed, NLM LactMed, and Drugs@FDA. The mobile version of a resource is used when available.
Smart Phones accessing the main Drug Portal site will be taken the mobile site.
The Drug Information Portal (http://druginfo.nlm.nih.gov) is a free Web resource from the NLM that provides an informative, user friendly entry-way to current drug information for over 32,000 drugs. Links to sources span the breadth of the NLM, the National Institutes of Health (NIH), and other government agencies. Current information regarding consumer health, clinical trials, AIDS–related drug information, MeSH pharmacological actions, PubMed biomedical literature, and physical properties and structure is easily retrieved by searching on a drug name. A varied selection of focused topics in medicine and drug–related information is also available from displayed subject headings.
For a full list of available apps and mobile websites, visit our NLM Gallery of Mobile Apps and Sites at: http://www.nlm.nih.gov/mobile/
- 5 Recent Changes to the PubMed Interface (intellogist.wordpress.com)
- Haz-Map (occupational health database) redesigned for web and mobile versions (jflahiff.wordpress.com)
- Correction: NLM Does Not Charge for PubMed Data (scholarlykitchen.sspnet.org)
- [Infographic] Making Patient Experience a Priority & Link to Other Infogaphics by the Author (jflahiff.wordpress.com)
When adults are advised by their health care professional to use a medication, they expect to receive information—backed up by data from studies—on the correct and safe dose to take. For drugs used in children, this information may not be available because historically not all products are studied in children.
To fix this situation, Congress passed legislation to increase pediatric studies and incorporate the resulting information in labeling. This is a key point because medicines often affect children differently from the way they work in adults.
The Food and Drug Administration (FDA) has been working hard on this project. To make it easier for parents and health care professionals to find information on pediatric medications, the FDA created a database that covers medical products studied in children under recent pediatric legislation.
The Pediatric Labeling Information Database is a one-stop resource. You can search for information by the product’s commercial or chemical name, or by the condition for which it was studied. FDA’s Office of Pediatric Therapeutics (OPT), which focuses on safety, scientific, and ethical issues that arise in pediatric clinical trials or after products are approved for use in children, developed the tool in collaboration with another branch of the agency, the Center for Drug Evaluation and Research.
From the 23 January Medical News Today article
The impact of efforts by the U.S. Food and Drug Administration to notify the general public and health care providers about unanticipated risks from approved medications has been “varied and unpredictable,” according to a systematic review of published studies about FDA warnings and alerts over the last 20 years.
Although some communication efforts had a strong and immediate effect, many had little or no impact on drug use or health behaviors and several had unintended consequences, researchers report in the journal Medical Care. …
…The FDA has several standard tools to disseminate new evidence about drug safety. These include “Dear Healthcare Provider” letters to prescribers*, “public health advisories” and “Safety Alerts” targeting the general public, and “black box warnings”** added to a label when a drug’s risks may be particularly severe or affect a large population. Despite numerous studies examining single alerts, advisories and label changes, no prior study has systematically examined the effect of these risk communications….
[Article summarizes the effectiveness of 4 categories of communication]
…Part of the problem, the authors emphasize, is the challenge of communicating complex risk messages to a large, diverse audience. “The most effective communications were the simplest, those that were specific, where alternatives were available, and where the messaging was reinforced over time,” said Stacie Dusetzina, PhD, lead author from Harvard Medical School.
*No direct links to “Dear Healthcare Provider” letters at http://www.fda.gov/Drugs/ResourcesForYou/HealthProfessionals/default.htm
However, individual letters can be found through using search engines, as a recent one for the drug Promacta
- Beauty Byte: FDA Orders “Black Box” Warning For Botox (bellasugar.com)
- Risk Strategy Requirement Change For Low Platelet Counts Drugs, Nplate And Promacta – FDA (medicalnewstoday.com)
- FDA favors more risk info on birth control pills (goerie.com)
- Regulation and drug safety (blacktriangle.org)
- FDA favors more risk info on birth control pills (sfgate.com)
Concerned about the safety of your drugs or medical advices? Wish to report a serious medical product problem online?
The US Food and Drug Agency (FDA) can help.
Medwatch is the FDA gateway for clinically important safety information and reporting serious problems with human medical products.
- DailyMed (National Library of Medicine)
Current Drug Prescribing Information
- Medication Guides
- Potential Signals of Serious Risks/New Safety Information Identified from the Adverse Event Reporting System (AERS)
- Postmarketing Drug and Biologic Safety Evaluations
Evaluations performed 18 months after drug approval, or after its use by 10,000 individuals.
- Current Drug Shortages
- Recalls and Alerts
Medwatch also encourages anyone to report serious problems with human medical products
- Report a Serious Medical Product Problem Online
- Reporting Unlawful Sales of Medical Products on the Internet
Want to stay informed with MedWatch updates? Here are some options…
Now available for free in the iTunes store!
Stay up to date with the latest news and government safety alerts for the prescription medicines you take. Submit any side effects you experience to the US Food and Drug Administration (FDA) to make drugs safer for everyone.
MedWatcher is a mobile tool for both healthcare professionals and the general public.
- Addition Of New Infant Acetaminophen Concentration, 160 Mg/5 ML, Says FDA (medicalnewstoday.com)
- FDA Targets Risks From Reused Medical Devices (fda.gov)
- An important FDA advisory update (in my dreams) (medcitynews.com)
- FDA: Do not use ShoulderFlex Massagers (gloucestercitynews.net)
- FDA Warns of Celexa Heart Risk (webmd.com)
- Pradaxa Benefit Outweighs Bleeding Risk – ABC News (abcnews.go.com)
- HCG Weight Loss Products Removed from the Market (fdarecalls.wordpress.com)
- Product Recall: Nostrilla Nasal Spray (habwwe.wordpress.com)
- FDA: Celexa May Damage Heart at High Doses (earlsview.com)
- Nostrilla Nasal Decongestant Recalled – Oct 2011 (wholefoodandmore.net)
- Risk Strategy Requirement Change For Low Platelet Counts Drugs, Nplate And Promacta – FDA (medicalnewstoday.com)